Juno Therapeutics Inc (NASDAQ:JUNO) traded up 16% on Wednesday . The stock traded as high as $35.00 and last traded at $32.23, with a volume of 10,966,458 shares trading hands. The stock had previously closed at $27.79.

Several research analysts recently commented on JUNO shares. FBR & Co reaffirmed a “buy” rating and issued a $73.00 price target on shares of Juno Therapeutics in a research note on Saturday, April 9th. Leerink Swann reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Thursday. SunTrust Banks Inc. reaffirmed a “buy” rating and issued a $50.00 price target on shares of Juno Therapeutics in a research note on Wednesday, April 20th. Cowen and Company started coverage on shares of Juno Therapeutics in a research note on Thursday, May 5th. They issued an “outperform” rating and a $55.00 price target on the stock. Finally, Barclays PLC started coverage on shares of Juno Therapeutics in a research note on Wednesday, July 6th. They issued an “equal weight” rating and a $48.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Juno Therapeutics has a consensus rating of “Buy” and a consensus target price of $53.11.

The firm’s 50 day moving average price is $40.37 and its 200-day moving average price is $38.13. The stock’s market cap is $2.91 billion.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.26. The firm had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $4.83 million. During the same quarter last year, the firm posted ($0.30) earnings per share. On average, equities analysts predict that Juno Therapeutics Inc will post ($2.28) earnings per share for the current fiscal year.

In other Juno Therapeutics news, General Counsel Bernard J. Cassidy sold 3,200 shares of the company’s stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $43.12, for a total value of $137,984.00. Following the transaction, the general counsel now owns 57,933 shares of the company’s stock, valued at $2,498,070.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Bernard J. Cassidy sold 3,116 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $39.03, for a total transaction of $121,617.48. Following the sale, the general counsel now owns 55,511 shares in the company, valued at $2,166,594.33. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in the company. BBR Partners LLC purchased a new stake in Juno Therapeutics during the fourth quarter worth $1,539,000. BNP Paribas Arbitrage SA raised its stake in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 10,884 shares during the last quarter. Stevens Capital Management LP purchased a new stake in Juno Therapeutics during the fourth quarter worth $2,315,000. Swiss National Bank purchased a new stake in Juno Therapeutics during the fourth quarter worth $2,603,000. Finally, ProShare Advisors LLC purchased a new stake in Juno Therapeutics during the fourth quarter worth $3,674,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.